Authors' Reply to “Translating Palbociclib to the Clinic for DIPG - What Is Truly Achievable?”

EBioMedicine - Netherlands
doi 10.1016/j.ebiom.2019.06.025
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Editorial: Tofacitinib and Biologics for Moderate-To-Severe Ulcerative Colitis-What Is Best in Class? Authors’ Reply

Alimentary Pharmacology and Therapeutics
HepatologyPharmacologyGastroenterology
2018English

Screening for Breast Cancer: What Truly Is the Benefit?

Canadian Journal of Public Health
MedicineEnvironmentalPublic HealthOccupational Health
2013English

Authors' Reply to Nussey

British Medical Journal
Medicine
2013English

The Epothilones: Translating From the Laboratory to the Clinic

Clinical Cancer Research
Cancer ResearchOncology
2008English

Authors' Reply to the Referees' Comments

2019English

Mistake Is to Myth What Pretense Is to Fiction: A Reply to Goodman

Philosophia (United States)
Philosophy
2017English

Authors Reply Letter to the Reviewers

2020English

Reply to Letter: What Is the Meaning of “Early CAG”?

Resuscitation
Emergency NursingEmergency MedicineCardiovascular MedicineCardiology
2020English

264. Translating RNAi Therapy for Spinocerebellar Ataxia 1 (SCA1) to the Clinic

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy